| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/14/2006 | EP1668013A1 Pyrazolopyrrole derivatives as protein kinase inhibitors |
| 06/14/2006 | EP1667998A2 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
| 06/14/2006 | EP1667978A2 Isoquinolinone potassium channel inhibitors |
| 06/14/2006 | EP1667723A1 Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness |
| 06/14/2006 | EP1667722A1 Combinations of alpha-2-delta ligands and acetylcholinesterase inhibitors |
| 06/14/2006 | EP1667721A2 Combinations of a vegf receptor inhibitor with other therapeutic agents |
| 06/14/2006 | EP1667720A1 Combination of a histone deacetylase inhibitor with a death receptor ligand |
| 06/14/2006 | EP1667719A1 Treatment of gastrointestinal stromal tumors with imatinib and midostaurin |
| 06/14/2006 | EP1667697A2 Method to treat the side effects associated with non steroidal anti-inflammatory drugs using microorganisms of the genus bifidobacterium. |
| 06/14/2006 | EP1667692A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist |
| 06/14/2006 | EP1667684A1 Use of chk1 inhibitors to control cell proliferation |
| 06/14/2006 | EP1667677A1 Composition for treating inflammatory bowel disease |
| 06/14/2006 | EP1667674A2 A method of healing skin wounds in mammals and a composition therefor |
| 06/14/2006 | EP1667657A1 Topical aerosol foams |
| 06/14/2006 | EP1667655A1 New use, pharmaceutical preparations as well as a process for their production |
| 06/14/2006 | EP1667518A2 Gamma-tocopherol treatment for cystic fibrosis |
| 06/14/2006 | EP1471931A4 Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto |
| 06/14/2006 | EP1427420B1 Use of a combination comprising 4-pyridylmethylphthalazines for cancer treatment |
| 06/14/2006 | EP1393075A4 Methods of screening and using inhibitors of angiogenesis |
| 06/14/2006 | EP1347778B1 Behavior chemotherapy |
| 06/14/2006 | EP1335701B1 Anti-adiposis topical treatment composition based on garlic bulb extracts |
| 06/14/2006 | EP1309703B1 Kallikrein gene |
| 06/14/2006 | EP1309315B1 Rapidly disintegrating oral formulation of valdecoxib |
| 06/14/2006 | EP1286667B1 Composition for the treatment and/or the prevention of osteoporosis and/or inflammatory joint diseases |
| 06/14/2006 | EP1266227B1 Synergistic activation of regulatory elements by rel proteins and a steroid receptor |
| 06/14/2006 | EP1261361B1 Oral, nasal and pulmonary dosage formulations of copolymer 1 (glatiramer acetate) |
| 06/14/2006 | EP1255558B1 Anti-april antibodies and hybridoma cells |
| 06/14/2006 | EP1214324B1 MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPases) |
| 06/14/2006 | EP1210100B1 Method of treating traumatic brain using non-steroidal anti-inflammatory drugs |
| 06/14/2006 | EP1175205B1 Solid dispersion comprising ritonavir, fenofibrate or griseofulvin |
| 06/14/2006 | EP1173186B1 Use of tagatose to enhance key blood factors |
| 06/14/2006 | EP1157704B1 Spla2 inhibitors for the treatment of ischaemic reperfusion injury |
| 06/14/2006 | EP1135115B1 Use of sibutramine for the treatment of disorders of the central nervous system secondary to organic impairments |
| 06/14/2006 | EP1119370B1 Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway |
| 06/14/2006 | EP1071468B1 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor |
| 06/14/2006 | EP1069890B1 Incorporation of active substances in carrier matrixes |
| 06/14/2006 | EP1033129B1 Antimicrobials for treating peptic ulcer |
| 06/14/2006 | EP0879035B1 Bismuth-containing compositions in topical dosage forms |
| 06/14/2006 | DE102005059420A1 Paste useful for treating dermatological diseases of the oral mucosa, contains a virustatic agent in an anhydrous base that adheres to the mucosa |
| 06/14/2006 | DE102005055385A1 Arzneimittel zur hygienischen Applikation im Ohr Medicines for hygienic application in the ear |
| 06/14/2006 | DE102004059613A1 Zusammensetzung und Methode einer topischen Therapie von Neurodermitis Composition and method of topical treatment of atopic dermatitis |
| 06/14/2006 | CN1787834A One or several enzyme-containing compounds, dietetic food products and drugs produced from said compounds and the use therefor for medical purposes |
| 06/14/2006 | CN1787824A External preparation for improving coital function |
| 06/14/2006 | CN1787821A A method of treating an anxiety disorder |
| 06/14/2006 | CN1787820A Composition for improving cognition and memory |
| 06/14/2006 | CN1787816A Method and kit for regulation of microvascular tone |
| 06/14/2006 | CN1787814A Method for augmenting the antitumor activity of anti-cancer agents |
| 06/14/2006 | CN1787813A Treatment and/or prevention of non-viral epithelial damage |
| 06/14/2006 | CN1785429A Medicinal composition for treating peptic ulcer |
| 06/14/2006 | CN1785428A New lysozyme compound injection preparation |
| 06/14/2006 | CN1785192A Eye-drops prepns. contg. tetrandrine and its application for preparing medicine therewith |
| 06/14/2006 | CN1785162A Double-layered medicine tablets for eliminating Helicobacter pylori and its prepn. method |
| 06/14/2006 | CN1259315C Antagonists of MCP-1 function and methods of use thereof |
| 06/14/2006 | CN1259056C Use of adenosine A3 receptor agonist for inhibition of viral replication |
| 06/14/2006 | CN1259051C Medicines and medicinal kits |
| 06/14/2006 | CN1259049C Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
| 06/13/2006 | US7060836 Lactams as tachykinin antagonists |
| 06/13/2006 | US7060828 Angiogenosis inhibitor; anticancer agents |
| 06/13/2006 | US7060733 Methods for treating pancreatitis with curcumin compounds and inhibitors of reactive oxygen species |
| 06/13/2006 | US7060732 Antiacne; skin disorders; packaged separately |
| 06/13/2006 | US7060730 Rapidly absorbed liquid compositions |
| 06/13/2006 | US7060720 Compounds useful for treating or preventing IMPDH associated disorders, such as transplant rejection and autoimmune diseases and inhibitors of inosine-5'-monophosphate dehydrogenase). The compounds and pharmaceutical compositions |
| 06/13/2006 | US7060718 Novel arylsulfonanilide derivatives and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly cancer, psoriasis, vascular |
| 06/13/2006 | US7060717 Phosphodiesterase inhibitor; antiinflammatory agents; antiallergens; respiratory system disorders; wound healing agents |
| 06/13/2006 | US7060696 Chelated 8-hydroxyquinoline and use thereof in a method of treating epithelial lesions |
| 06/13/2006 | US7060504 High mobility group proteins; diagnostic monitoring the severity or potential lethality of sepsis or septic shock, measuring the serum protein concentration of patient, treating weight loss or obesity |
| 06/13/2006 | US7060481 Comprises peptide for diagnosing and treating inflammatory, tumor, arthritic and nervous system disorders |
| 06/13/2006 | US7060454 Method for sorting antifungal molecules acting on the glucanosyltransferase activity |
| 06/13/2006 | US7060453 determination of the level of glucose in non-blood sample (i.e. urine and hair) containing red blood cells; measuring the volume of blood (by measuring hemoglobin) and the amount of glucose in the sample and calculating the level of glucose in the blood based on those measurements |
| 06/13/2006 | US7060449 Method of preparing GALR2 receptors composition |
| 06/13/2006 | US7060447 Protein localization assays for toxicity and antidotes thereto |
| 06/13/2006 | US7060298 Comprises biocompatible hydrophilic cationic microparticles and cell adhesion promoter implanted into the lower esophageal sphincter |
| 06/13/2006 | US7060295 Formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus |
| 06/13/2006 | US7060290 Phosphocholine linked prodrug derivatives |
| 06/13/2006 | US7060289 Topical glycopyrrolate product |
| 06/13/2006 | US7060285 Dispersions for the formulation of slightly or poorly soluble agents |
| 06/13/2006 | US7060278 Bv8 nucleic acids and polypeptides with mitogenic activity |
| 06/13/2006 | US7060262 Administering granulocyte colony stimulating factor; Crohn's disease |
| 06/13/2006 | US7060254 Aerosol; heating thin film on solid support; vaporization with air flow |
| 06/13/2006 | CA2302601C Transdermal therapeutic system comprising a reservoir-type pressure-sensitive adhesive layer and a back layer with uni-directional resilience |
| 06/08/2006 | WO2006060507A2 Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders |
| 06/08/2006 | WO2006059897A1 Sphingolipids in treatment and prevention of steatosis and of steatosis or of hepatotoxicity and its sequelae |
| 06/08/2006 | WO2006059785A1 Development of bioactive agent using dendritic cell differentiation-inducing factor |
| 06/08/2006 | WO2006059777A1 Remedy for alzheimer’s disease |
| 06/08/2006 | WO2006059730A1 Composition for body fat reduction |
| 06/08/2006 | WO2006059713A1 Preventive and/or therapeutic agent for drug dependence |
| 06/08/2006 | WO2006059637A1 Agent for diagnosing, preventing and treating adhesion with the use of ccr8 inhibitor |
| 06/08/2006 | WO2006059423A1 Medicine for treatment of disease caused by hyperstimulatory cytotoxicity and therapeutic method |
| 06/08/2006 | WO2006013427A3 Treatment of ccr2 mediated diseases or disorders |
| 06/08/2006 | WO2005118778A8 Method for ex vivo isolating and expanding human cornea stem cells and uses thereof |
| 06/08/2006 | WO2005093036A3 Inhibitors of siderophore biosynthesis in fungi |
| 06/08/2006 | WO2005082329B1 Process for the preparation of solid dosage forms of valsartan and hydrochlorthiazide |
| 06/08/2006 | WO2005076987A3 Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent |
| 06/08/2006 | WO2005070434A3 Treatment of aromatase inhibitor therapy-related osteoporosis |
| 06/08/2006 | WO2005037219A3 Disinfecting teat care compositions |
| 06/08/2006 | WO2005014607A3 Antisense modulation of stearoyl-coa desaturase expression |
| 06/08/2006 | WO2004050020A3 Improved opioid pharmaceutical compositions |
| 06/08/2006 | WO2003077857A3 N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7- carboxamides useful as hiv integrase inhibitors |
| 06/08/2006 | WO2003076571A3 Cancer-linked gene as target for chemotherapy |
| 06/08/2006 | US20060123498 Paks as modifiers of the chk pathway and methods of use |